Logo

Biogen's Vumerity (diroximel fumarate) Receives the EC's Approval for the Treatment of Relapsing-Remitting Multiple Sclerosis

Share this

Biogen's Vumerity (diroximel fumarate) Receives the EC's Approval for the Treatment of Relapsing-Remitting Multiple Sclerosis

Shots:

  • The approval is based on the data from PK bridging studies and P-III EVOLVE-MS-2 study to evaluate the GI tolerability of Vumerity vs Tecfidera in patients with relapsing-remitting MS
  • In the EVOLVE-MS-2 study, the therapy demonstrated a low rate of overall treatment discontinuation due to GI tolerability (1.6% vs 6%). Additionally, flushing was reported in patients treated with Vumerity & Tecfidera (32.8% & 40.6%), no serious events of flushing or discontinuations were observed
  • Vumerity is oral fumarate & has received the US FDA approval in Oct 2019. The therapy is also approved in Great Britain and Switzerland

/ article Ref: Globe Newswire | ImageBiogen

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions